Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (DE:MOL0)
FRANKFURT:MOL0
MOL0 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Moleculin Biotech News
MOL0 FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was €6.45 and its highest was €6.60 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $10.71M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 20, 2026 which is in 65 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Nov 17, 2025. The company reported -€14.619 earnings per share for the quarter, missing the consensus estimate of -€5.656 by -€8.963.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -5.25.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 3,079,229 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -€14.619 in its last earnings report, missing expectations of -€5.656. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in DE:MOL0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
MOL0 Stock 12 Month Forecast
Average Price Target
€20.90
▲(224.09% Upside)